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2013Cardiovascular diseases (CVD) remain the grim reaper’s
primary calling card.1 Mortality and morbidity from CVDs,
both coronary heart disease (CHD) and stroke, have declined in
most high income countries and presently the largest burden
has shifted tomiddle and low income countries.2 Indeed, India
and China account for more cases of CVD than all developed
countries put together.1 Unique characteristics of CVD in low
and middle income countries such as India are premature
onset, high mortality, increasing burden and regional varia-
tions.3 The good news is that most premature CVD can be
prevented and controlled by a combination of changes in
policy, healthcare programs, process implementation, physi-
cian education and task shifting, practice paradigms,
population-wide interventions, primary prevention, better
patient management and patient empowerment for risk fac-
tors and disease prevention and management (Table 1).1. UN high level meeting on non-
communicable diseases and WHO
United Nations (UN) convened a special high-level meeting to
develop consensus on prevention and control of non-
communicable diseases (NCD) in September 2011. The main
focus of this meeting was worldwide epidemic of premature
non-communicable diseases, especially in developing coun-
tries.4 In the last 18 months important targets for action have
been proposed.5 Almost all the targets are focused on car-
diovascular diseases (Table 2).2. Global forum on CVD prevention in clinical
practice
To achieve these targets, there is a need to form an alliance of
all interested stake holders in cardiovascular disease pre-
vention and management to facilitate the implementation of
United Nation (UN) declaration on prevention and control of
cardiovascular diseases (25  25 resolution).6 European Soci-
ety of Cardiology (ESC) and European Association for Car-
diovascular Disease Prevention and Rehabilitation (EACPR)
organized a meeting during the EuroPrevent 2013 conferenceat Rome on 18th April 2013 to discuss possibilities to form an
organization that would focus on CVD prevention in clinical
practice. The invitees included representatives from World
Health Organization and elected officials of World Heart Fed-
eration, American Heart Association, European Society of
Cardiology, American Council of Cardiovascular Prevention
and Rehabilitation, American Society of Preventive Cardiol-
ogy, Canadian Society of Preventive Cardiology, Inter-
American Society of Cardiology and national representatives
from twenty countries including large countries such as
China, India, Saudi Arabia, Japan, Brazil, Russia, etc, along
with many sub-national organizations. Details of the meeting
are available at ESC website.7
The targets proposed by the WHO (Table 2) were presented
at the global forum by Shanthi Mendis (WHO, Geneva). She
highlighted that policy initiatives at governmental level are
important for control ofmost of the cardiovascular risk factors
and have immediate impact in reducing morbidity and mor-
tality. Such initiatives have led to significant decline in CVD
mortality in Western Europe and North America by 30e80% in
last three decades.8 She pointed out that six of the proposed
targets (physical inactivity, sodium intake, tobacco use, high
BP, drug therapy coverage and availability of essential medi-
cines and technologies) are focused on cardiovascular dis-
eases. WHO and World Heart Federation have developed
specific directives for policy changes focused on strategies for
effective national CVD control program with financial and
management support, risk factor control programs on smok-
ing cessation, enhanced physical activity, dietary modulation,
and better risk factor and disease management.9 These ini-
tiatives were presented by Johanna Ralston (World Heart
Federation, Geneva). She suggested a multipronged policy
initiative, endorsed by the WHO, with focus on implementing
national CVD control programs, adequate healthcare financ-
ing and public health insurance for preventive and curative
treatment, smoking and tobacco control programs, promotion
of healthy diet with legislative control of saturated fats, trans
fats, salt and alcohol and promotion of fruits and vegetables;
increased physical activity through better urban planning,
worksite and school-based interventions and aggressive pri-
mary prevention for control of hypertension, dyslipidemia
and diabetes.
Table 2 e Nine proposed voluntary global targets for
prevention and control of non-communicable diseases
(mainly cardiovascular disease) to be achieved by 2025:
WHO Global Action Plan.
Domain Intervention
1 Mortality and morbidity 25% relative reduction in overall
mortality from cardiovascular
disease, cancer, diabetes or chronic
respiratory diseases
2 Harmful use of alcohol 10% relative reduction in harmful
use of alcohol
3 Physical inactivity 10% relative reduction in
prevalence of insufficient physical
activity
4 Salt/sodium intake 30% relative reduction in mean
population intake of salt/sodium
5 Tobacco use 30% relative reduction in
prevalence of current tobacco use
in aged 15þ years.
6 Raised blood pressure 25% relative reduction in the
prevalence of raised BP or contain
the prevalence of raised BP
7 Diabetes and obesity Halt the rise in diabetes and obesity
8 Drug therapy to prevent
heart attacks and strokes
At least 50% of eligible people
receive drug therapy and
counseling to prevent heart attacks
and strokes.
9 Essential medicines and
basic technologies for
treatment
80% availability of affordable basic
technologies and essential
medicines (generics) required to
treat major non-communicable
disease in both public and private
facilities.
Table 1 e Nine P’s of prevention.
Domain Intervention
1 Policy change Strengthening of policies related to smoking,
tobacco use, alcohol abuse, dietary fats and
trans fats intake, fruits and vegetable intake,
increased physical activity, school health
programs, worksite intervention, public
health education and promotion of health
literacy.
2 Program
development
Specific programs to address four major
behavioral domains e smoking/tobacco use,
alcohol abuse, healthy diet, physical activity;
three risk factorse high blood pressure, high
cholesterol and diabetes; and better disease
management.
3 Process
implementation
Development and implementation of
suitable practice algorithms for use by
various healthcare professionals and other
stake holders.
4 Physician
education
Medical education to be focused on all the
major health problems in the country;
specific focus on non-communicable
diseases. Changes in undergraduate and
postgraduate education for all healthcare
providers.
5 Practice paradigm Shift from ad-hoc acute disease model to
continuous care chronic disease model.
6 Population-wide
interventions
Interventions to control primordial
cardiovascular risk factors e smoking,
alcohol abuse, physical inactivity and
unhealthy diet.
7 Primary prevention Control of important risk factors e smoking
and tobacco use, high blood pressure, high
LDL cholesterol, low HDL cholesterol,
diabetes and the metabolic syndrome using
appropriate lifestyle and therapeutic
strategies.
8 Patient
management
Acute cardiovascular care using coronary
care units and stroke units. Effective long
term care and secondary prevention.
9 Patient
empowerment
Promotion of risk factor and disease self
management; medication and lifestyle
adherence.
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ESC initiatives were discussed by EACPR president Stefan
Gielen (Halle), DavidWood (London), and Ian Graham (Dublin)
while international experiences were presented by Sidney
Smith (Atlanta), Donna Arnett (American Heart Association,
Dallas), and others. Focus was to translate the prevention and
management strategies into practice.7 Better primary pre-
vention including control of hypertension, hyper-
cholesterolemia and diabetes was stressed.
There are limited data on primary prevention in different
countries. The most robust data are available in Europe and
USA and shows poor adherence to lifestyle changes and drugs
advised for control of risk factors.10 Reasons were discussed
and strategies proposed including use of community health
workers and combination polypharmacy. There is poor
implementation of secondary prevention approaches in dif-
ferent countries of the world. EUROASPIRE studies in Europe11
and PURE study internationally12 reported significant gaps in
use of various evidence based therapies in patients withknown cardiovascular diseases. Strategies to improve secon-
dary prevention practices were also presented and WHO
guidelines on prevention of recurrent heart attacks and
strokes in low and middle income populations were dis-
cussed.13 Representatives from several countries including
China, India, Russia, Brazil, Canada, USA, Saudi Arabia, Iran,
etc presented national data and highlighted needs and chal-
lenges for prevention in their nation.73. Cardiological Society of India at the global
forum
Presentation from India highlighted the high mortality rates,
premature onset of disease, regional variations and increasing
burden from cardiovascular diseases.3 A brief outline of the
National Program on Control of Cardiovascular Disease, Dia-
betes, Cancer and Stroke was presented. Currently this pro-
gram is focused on screening of risk factors using tool of
opportunistic screening at primary and secondary healthcare
centers in 100 districts of the country. It is been planned to
merge this program into the existing National Rural Health
Mission and proposed National Urban Health Mission or
National Health Mission.14
A multipronged strategy to improve practices for pre-
vention and management of cardiovascular diseases was
presented (Table 3). Various policy interventions and
Table 3 e Existing and proposed initiatives for
cardiovascular disease prevention and control in India.
Domain Intervention
Policy initiatives A. Social policies
 Tobacco control policies, FCTC
 Right to education act
 Job guarantee
 Women’s health promotion
programs
B. Financial policies
 Universal health insurance
 Below-poverty-line insurance
C. Pharmaceutical policies
 Increase in essential drug list
 Drug price control
 Free supply of essential
medicines
Population based
interventions
A. School health programs
 Mid-day meal scheme
 Physical education programs
 Health literacy
B. Worksite interventions
C. High-risk population interventions
High risk approach A. Enhancing professional education
(physicians, etc)
B. Facilities for acute disease
management
C. Task shifting for risk factor man-
agement and long-term care
D. Use of technology and personalized
medicine
Table 4 e Proposals for international collaborations in a
global alliance for CVD prevention and management.
Domain Intervention
Health policy 1. International advocacy for inclusion of
CVD In national development agenda in
India.
2. Creation of barriers in international trade
in CVD unfriendly practices (tobacco,
alcohol, oils, processed foods)
3. Promotion of CVD healthy policies. Low-
ering of World Trade Organization bar-
riers for evidence-based cardiovascular
pharmaceuticals.
Healthcare
systems
1. Technological support for development
of CVD management infrastructure.
2. Processes for rapid appropriate-technol-
ogy-transfer.
3. Better medical and health education.
Healthcare
delivery
1. Robust primary care, focused on overall
health and not on vertical disease control
programs.
2. Models for district hospital based
advanced CVD care.
3. Development of tertiary care facilities as
referral centers.
4. Nurse-practitioner and pharmacists
based healthcare delivery.
5. Mechanisms for clinical audits and
feedbacks using scientifically validated
methods.
Healthcare
research
1. Clinical audits and registries as quality
improvement research tools. Lessons
from large ESC-European, UK and US
registries.
2. Technology transfer for creation of
registries.
3. Promotion of health services research.
4. Research in primary prevention.
5. Use of non-physician healthcare workers
for CVD management.
6. Use of polypills and other fixed dose
combinations in CVD prevention and
disease management.
7. Appropriateness criteria and issues of
over-treatment.
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These strategies can potentially lead to significant improve-
ment in prevention and control of cardiovascular disease in
India. Cardiological Society of India could collaborate with
various international agencies and organizations in this
effort. The following strategies were outlined (Table 4).
There is a need to create a CVD-friendly general climate in
India and CVD-friendly policies need to be developed among
politicians, press, physicians and patients. There should be a
rapid policy to program implementation pathway and there is
a need to link physicians with public health community.
Ultimately, it is the patient empowerment that would lead to
better prevention and control of CVD in India.4. The way forward
Themeeting concludedwith a call to form a global alliance for
CVDprevention. Professors Geilen andWood emphasized that
the alliance shall not overlap with theWorld Heart Federation
or issue guidelines itself, rather, it would play a role in stim-
ulating and assisting with guidelines and standards, educa-
tion and training, health service provision, research and
leadership. Each organization with a professional role incardiovascular prevention and rehabilitation can send two
representatives to the alliance which will be led by six such
nominated representatives perWHO-defined region for a total
of 36 members in the leadership forum. A secretary, deputy
and 10 ambassadors will be elected from among the repre-
sentatives for a 3-year term to execute the alliance strategies.
A five-pronged agenda to address strategically important
issues in prevention, management and control of car-
diovascular was adopted. The agenda included focus on (i)
development of standards of care for CVD prevention and
management and guidelines, (ii) education and training of
health professionals of all categories, (iii) health services
strengthening for preventive and rehabilitative care, (iv) pro-
motion of research in cardiovascular epidemiology and pre-
vention, and (v) building national and international leadership
in prevention and rehabilitation.
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